Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

139 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is Examination of the superiority of a combination of vinorelbine with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in advanced breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

NCT05296577

Breast Cancer

UNKNOWN PHASE2

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

NCT00709618

Neoplasms, Breast

TERMINATED PHASE2

Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer

NCT00146549

Breast Cancer Stage IV Breast Cancer

COMPLETED PHASE3

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

NCT02768415

Breast Cancer

UNKNOWN PHASE2

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

NCT04903652

HER2-positive Advanced Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Her2-negative Metastatic Breast Cancer Her2-negative Locally Advanced Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vinorelbin and Everolimus

Group Type EXPERIMENTAL

Vinorebine, Everolimus

Intervention Type DRUG

Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress

standard therapy

Vinorelbin

Group Type OTHER

Vinorelbine

Intervention Type DRUG

Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vinorebine, Everolimus

Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress

Intervention Type DRUG

Vinorelbine

Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1 .Dated and signed patient informed consent before start of any in the protocol specified procedures 2. Histologically or cytologically confirmed Her2/neu negative, metastatic or locally advanced breast cancer, including inoperable local relapse, with measurable or non-measurable lesions for which

* a palliative second line chemotherapy is indicated. Antihormone palliative pretreatments do not count as separate treatment lines
* treatment with anthracycline and/or taxanes has failed or is not suitable
* which cannot be adequately treated by operation or radiotherapy on its own 3. An exclusive anti-hormone therapy is not indicated for the patient 4. ECOG Performance Status of 0-2 5. Women \>= 18 years of age 6. Life expectancy of at least 12 weeks 7. Adequate bone marrow, liver and renal function (according to SmPC of Vinorelbine, Afinitor®) based on laboratory assessments raised within 7 days prior to start of study treatment:
* Haemoglobin \>= 9.0 g/dl
* Absolute neutrophil count (ANC) \>= 2/mm³
* Thrombocytes \>= 100/µl
* INR \>= 2
* Serum bilirubin =\< 1.5x upper limit of normal ( in patients with known Gilbert syndrome, total bilirubin =\< 3x upper limit of normal, with direct bilirubin =\< 1.5x upper limit of normal
* ALT and AST =\< 2.5x upper limit of normal (=\< 5x upper limit of normal in subjects with liver metastases)
* Serum cholesterol =\< 300 mg/dl or 7.75 mmol/l and triglycerides =\< 2.5x upper limit of normal (with lipid lowering drugs permitted)
* Serum creatinin =\< 2x upper limit of normal 8. Documentation of a negative pregnancy test in women of childbearing potential within 7 days prior to start of study. Sexual active pre-menopausal women are required to use adequate contraception throughout the duration of the study, except for oestrogen containing contraceptives

Exclusion Criteria

1. Previous treatment with Vinorelbine or an inhibitor of mTOR
2. Treatment with other study medication within 28 days before start of treatment
3. Patients who have received prior radiotherapy to ≥ 25% of the bone marrow
4. Other tumours in the previous 5 years with exception of an adequately treated basal cell carcinoma of the skin or a preinvasive cervix carcinoma
5. Simultaneous use of known CYP3A4 inducers (e.g. Phenytoin, Rifampicin) or inhibitors of this enzyme (e.g. Itraconazole, Ketoconazole), therefore also use of mistletoe, St John's wort or grapefruit juice
6. Patients to whom at least one of the conditions applies:

* Substance abuse
* medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results as judged by the investigator
* Legal incapacity or limited legal capacity
* Subjects who are unable to take oral medication
* Any condition that could jeopardise the safety of the patient and their compliance in the study as judged by the investigator
7. History of cardiac dysfunction including one of the following:

* Myocardial infarction by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function
* History of documented congestive heart failure (NYHA ≥ 3)
* Documented cardiomyopathy
8. Known HIV infection or chronic hepatitis B or C or history of hepatitis B / C
9. Active clinically relevant infection (\> grade 2 NCI-CTC Version 4.03)
10. Clinical or radiological detection of CNS metastases
11. Patients receiving concomitant immunosuppressive agents or chronic use of corticosteroids at the time of study entry except in cases outlined below:

* topical applications (e.g. rash,) inhaled sprays, (e.g. obstructive airway diseases) eye drops or local injections (e.g. intraarticular) are allowed
12. Active bleeding diathesis or an oral anti-vitamin K medication (except low-dose warfarin and aspirin or equivalent, as long as the INR ≤ 2)
13. Kidney function disorder requiring dialysis
14. Seriously impaired liver function (Child-Pugh, class C)
15. Known hypersensitivity reaction to Vinorelbine or Everolimus
16. Pregnant or breast-feeding subjects

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No